These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32715412)

  • 21. Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis.
    Lattanzi S; Brigo F; Trinka E; Zaccara G; Cagnetti C; Del Giovane C; Silvestrini M
    Drugs; 2018 Nov; 78(17):1791-1804. PubMed ID: 30390221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Highly purified cannabidiol improves stability and postural tone in adult patients with Lennox-Gastaut syndrome: A case series.
    Calvello C; Fernandes M; Lupo C; Placidi F; Izzi F; Bianco C; Celeste MG; Mercuri NB; Liguori C
    Epileptic Disord; 2023 Feb; 25(1):74-79. PubMed ID: 36946334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of seizure frequency on quality of life in patients with Lennox-Gastaut syndrome or Dravet syndrome.
    Auvin S; Damera V; Martin M; Holland R; Simontacchi K; Saich A
    Epilepsy Behav; 2021 Oct; 123():108239. PubMed ID: 34375802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Caregivers' Perspectives on the Impact of Cannabidiol (CBD) Treatment for Dravet and Lennox-Gastaut Syndromes: A Multinational Qualitative Study.
    Marshall J; Skrobanski H; Moore-Ramdin L; Kornalska K; Swinburn P; Bowditch S
    J Child Neurol; 2023 May; 38(6-7):394-406. PubMed ID: 37455396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient and Caregiver Health State Utilities in Lennox-Gastaut Syndrome and Dravet Syndrome.
    Lo SH; Lloyd A; Marshall J; Vyas K
    Clin Ther; 2021 Nov; 43(11):1861-1876.e16. PubMed ID: 34774333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clobazam is efficacious for patients across the spectrum of disease severity of Lennox-Gastaut syndrome: post hoc analyses of clinical trial results by baseline seizure-frequency quartiles and VNS experience.
    Wheless JW; Isojarvi J; Lee D; Drummond R; Benbadis SR
    Epilepsy Behav; 2014 Dec; 41():47-52. PubMed ID: 25282105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study.
    Thiele E; Marsh E; Mazurkiewicz-Beldzinska M; Halford JJ; Gunning B; Devinsky O; Checketts D; Roberts C
    Epilepsia; 2019 Mar; 60(3):419-428. PubMed ID: 30740695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
    Lattanzi S; Trinka E; Russo E; Striano P; Citraro R; Silvestrini M; Brigo F
    Drugs Today (Barc); 2019 Mar; 55(3):177-196. PubMed ID: 30938373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comment on "Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome".
    Hollenack K; Marshall J
    Pharmacoeconomics; 2021 Apr; 39(4):473-475. PubMed ID: 33674999
    [No Abstract]   [Full Text] [Related]  

  • 31. Authors' Reply to Comment on "Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome".
    Neuberger EE; Carlson JJ; Veenstra DL
    Pharmacoeconomics; 2021 Apr; 39(4):477-478. PubMed ID: 33674997
    [No Abstract]   [Full Text] [Related]  

  • 32. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy.
    Franco V; Perucca E
    Drugs; 2019 Sep; 79(13):1435-1454. PubMed ID: 31372958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cannabidiol use in patients with Dravet syndrome and Lennox-Gastaut syndrome: experts' opinions using a nominal group technique (NGT) approach.
    Bonanni P; Ragona F; Fusco C; Gambardella A; Operto FF; Parmeggiani L; Sartori S; Specchio N
    Expert Opin Pharmacother; 2023 Apr; 24(5):655-663. PubMed ID: 37021712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic evaluation of deep brain stimulation compared with vagus nerve stimulation and usual care for patients with refractory epilepsy: A lifetime decision analytic model.
    Chan HY; Wijnen BFM; Majoie MHJM; Evers SMAA; Hiligsmann M
    Epilepsia; 2022 Mar; 63(3):641-651. PubMed ID: 34967942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders.
    Golub V; Reddy DS
    Adv Exp Med Biol; 2021; 1264():93-110. PubMed ID: 33332006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Economic Impact of Acetabular Labral Tears: A Cost-effectiveness Analysis Comparing Hip Arthroscopic Surgery and Structured Rehabilitation Alone in Patients Without Osteoarthritis.
    Lodhia P; Gui C; Chandrasekaran S; Suarez-Ahedo C; Dirschl DR; Domb BG
    Am J Sports Med; 2016 Jul; 44(7):1771-80. PubMed ID: 27190068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Source of cannabinoids: what is available, what is used, and where does it come from?
    Specchio N; Pietrafusa N; Cross HJ
    Epileptic Disord; 2020 Jan; 22(S1):1-9. PubMed ID: 31941643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of perampanel for the treatment of primary generalized tonic-clonic seizures (PGTCS) in epilepsy: A Spanish perspective.
    Tremblay G; Howard D; Tsong W; Patel V; De Rosendo J
    Epilepsy Behav; 2018 Sep; 86():108-115. PubMed ID: 30001911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.